Alzheimer's disease (AD) is the most common form of dementia with more than 5.5 million patients in the USA, a number that will quadruple by 2047. The disease can be characterized as an accelerated loss of cognitive functioning to such an extent that it interferes drastically with a person
Aim 1. Using second generation high throughput sequencing to assess changes in chromatin modifications induced by nutritional signals and their role in the development and progression of cognitive performance and AD pathology.
Aim 2. To reveal genome-wide changes in LXR binding caused by HFD and thus to identify LXR targets whose transcriptional up- or down-regulation has a role in the development and progression of AD-like phenotype in model mice.
This study will address questions that are important for continuing research in a field highly relevant to human health - Alzheimer's disease and changes in chromatin modifications induced by nutritional signals and their role in the development and progression of this disease. The result from this study will help us to understand the interplay between important genes and proteins involved in cholesterol transport in brain, and how the knowledge about disturbed function of those proteins can help in developing new therapeutic strategies for slowing AD progression.
|Nam, Kyong Nyon; Mounier, Anais; Fitz, Nicholas F et al. (2016) RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of AÎ² oligomers. Sci Rep 6:24048|
|Mounier, Anais; Georgiev, Danko; Nam, Kyong Nyon et al. (2015) Bexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity. J Neurosci 35:11862-76|
|Fitz, Nicholas F; Tapias, Victor; Cronican, Andrea A et al. (2015) Opposing effects of Apoe/Apoa1 double deletion on amyloid-Î² pathology and cognitive performance in APP mice. Brain 138:3699-715|
|Lefterov, Iliya; Schug, Jonathan; Mounier, Anais et al. (2015) RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment. Neurobiol Dis 82:132-40|
|Koldamova, Radosveta; Fitz, Nicholas F; Lefterov, Iliya (2014) ATP-binding cassette transporter A1: from metabolism to neurodegeneration. Neurobiol Dis 72 Pt A:13-21|
|Koldamova, Radosveta; Schug, Jonathan; Lefterova, Martina et al. (2014) Genome-wide approaches reveal EGR1-controlled regulatory networks associated with neurodegeneration. Neurobiol Dis 63:107-14|
|Fitz, Nicholas F; Castranio, Emilie L; Carter, Alexis Y et al. (2014) Improvement of memory deficits and amyloid-Î² clearance in aged APP23 mice treated with a combination of anti-amyloid-Î² antibody and LXR agonist. J Alzheimers Dis 41:535-49|
|Cronican, Andrea A; Fitz, Nicholas F; Carter, Alexis et al. (2013) Genome-wide alteration of histone H3K9 acetylation pattern in mouse offspring prenatally exposed to arsenic. PLoS One 8:e53478|
|Fitz, Nicholas F; Cronican, Andrea A; Lefterov, Iliya et al. (2013) Comment on ""ApoE-directed therapeutics rapidly clear Î²-amyloid and reverse deficits in AD mouse models"". Science 340:924-c|
|Fitz, Nicholas F; Cronican, Andrea A; Saleem, Muzamil et al. (2012) Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. J Neurosci 32:13125-36|